Founded in 2007 with headquarters in Boulder, Colorado.
N30 Pharma is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis.
As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO.
N30 Pharma has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease.
- Reduced levels of GSNO are associated with cystic fibrosis
- GSNO, through nitric oxide signaling, is integral to the normal function of CFTR, the transmembrane regulator protein that is defective in cystic fibrosis
- Anti-inflammatory effects of GSNOR inhibitors relevant to cystic fibrosis include decreased NFκB activation, neutrophilic infiltration, and elastase-mediated lung injury
- Lead compound, N6022, has completed Phase 1 testing in healthy subjects, a proof of concept study in asthma, and is poised to enter clinical trials in cystic fibrosis in the first quarter of 2013